These settlement agreements attract concern from
competition regulators due to their potential to take the form of so - called «pay - for - delay» or «reverse payment» arrangements where a generic manufacturer agrees to delay the launch of a competing generic product in exchange for a transfer of value (monetary or otherwise) from the brand company....